A Phase 3 interventional study of Mirogabalin and Melatonin in Knee Arthritis Osteoarthritis, Postoperative Pain and Anxiety, sponsored by Beni-Suef University. Not yet recruiting at 1 site in Egypt. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Beni-Suef University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 599 studies in Pain, Postoperative with a site in Egypt — 133 open to participants now, 156 under way, 7 of them phase 3. Pain, Postoperative · Egypt.
Among the 599 studies in Pain, Postoperative with a site in Egypt, this one is the 191st largest by planned enrollment of the 590 interventional ones that give a count, is one of 73 that started in 2026, is one of 29 in phase 3, reaches primary completion later than 129 of the 155 other live ones, and was the 597th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →133 of the 599 studies in Pain, Postoperative with a site in Egypt are open now. Recruiting first, the newest first:
National Cancer Institute, Egypt · Sites in Egypt
Ages 18–65 · Women only
Ain Shams University · Sites in Egypt
Ages 50–70
Al-Azhar University · Sites in Egypt
Ages 20–40 · Men only
Cairo University · Sites in Egypt
Ages 25–45 · Women only
Sohag University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 50 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
599 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 59 · Phase 3 48 · Phase 4 52
First in 2012; this study’s year is marked. 73 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is close to the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 60 across the 590 interventional studies, 65 across the 9 observational. Of the 358 that completed or were terminated, 4 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 599 have an industry lead sponsor. The 10 most frequent:
Beni-Suef University is the lead sponsor of 350 studies on the registry; 124 are open to participants now.
Beni-Suef University has 9 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
64 of the studies in Pain, Postoperative with a site in Egypt that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07878156Phase 3Children's Cancer Hospital Egypt 57357Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery. | 2026-12-30 |
| NCT07370181Phase 3Assiut UniversityKetamine Irrigation Analgesia in Laparoscopic Cholecystectomy | 2027-02-01 |
| NCT07950852Phase 3Beni-Suef UniversityMirogabalin vs. Melatonin for Pain and Anxiety After Total Knee Arthroplasty Under Spinal Anesthesia | 2027-05 |
| NCT07047040Phase 3Assiut UniversityAnalgesic Efficacy of Pre-operative Dose of Ketorolac and Gabapentin | 2027-10-30 |
| NCT07855549Minia UniversityComparative Study Between Erector Spinae Plane Block Versus Combined Pectoralis and Serratus Interfascial Plane Blocks for Post-operative Analgesia After Thoracic Surgery. | 2026-11 |
Add all 64 to your calendar (.ics) → With an account.
Among the 599 studies in Pain, Postoperative with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Total knee arthroplasty (TKA) is frequently associated with moderate-to-severe postoperative pain, substantial opioid consumption, and preoperative anxiety. Although spinal anesthesia is preferred for TKA, it does not provide prolonged analgesia after the block resolves.
This prospective, randomized, double-blind, placebo-controlled trial aims to evaluate and compare the efficacy of perioperative oral mirogabalin versus melatonin versus placebo as opioid-sparing analgesic adjuncts in patients undergoing elective unilateral TKA under spinal anesthesia. The primary objective is to assess their impact on postoperative pain intensity and perioperative anxiety levels.
Preoperative anxiety affects 30% to 70% of patients undergoing total knee arthroplasty (TKA) and can exacerbate postoperative pain, increase opioid consumption, and delay recovery. Multimodal perioperative optimization within Enhanced Recovery After Surgery (ERAS) protocols is essential to address these challenges.
Mirogabalin is a novel, selective ligand of the α₂δ subunit of voltage-gated calcium channels with a long dissociation half-life, demonstrating analgesic and anxiolytic properties. Melatonin is an endogenous pineal hormone with well-characterized chronobiotic, sedative, anxiolytic, and antinociceptive actions. Despite their potential, no randomized controlled trial has directly compared mirogabalin and melatonin for perioperative optimization in TKA under spinal anesthesia.
Eligible consenting participants (aged 50-70 years, ASA I-III, scheduled for primary elective unilateral TKA under spinal anesthesia) will be randomized (1:1:1) to one of three parallel groups:
All patients will receive standardized intraoperative spinal anesthesia (hyperbaric bupivacaine + fentanyl) and standardized background multimodal analgesia (paracetamol, ketorolac, and intraoperative dexamethasone).
Outcomes assessed up to 48 hours postoperatively include Numeric Rating Scale (NRS) pain scores, Amsterdam Preoperative Anxiety and Information Scale (APAIS) scores, 24-hour and 48-hour cumulative opioid (nalbuphine) consumption, time to first rescue analgesia, sedation level (MOOA/S), sleep quality (SQS), time to first mobilization, hemodynamic stability, and adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive oral mirogabalin 10 mg at 10:00 PM on the night before surgery, 1 hour before planned spinal anesthesia, 10:00 PM on the day of surgery, and at 10:00 AM and 10:00 PM on the first postoperative day (Postoperative Day 1). All participants receive standardized spinal anesthesia (hyperbaric bupivacaine 0.5% + fentanyl 25 mcg) and multimodal background analgesia (paracetamol 1 g IV q6h, ketorolac 30 mg IV q12h, and intraoperative dexamethasone 8 mg IV).
Drug: Mirogabalin
Patients receive oral melatonin 10 mg at 10:00 PM on the night before surgery, 1 hour before planned spinal anesthesia, and 10:00 PM on the day of surgery. On Postoperative Day 1, patients receive a matching placebo tablet at 10:00 AM (to preserve blinding), followed by melatonin 10 mg at 10:00 PM. All participants receive standardized spinal anesthesia and identical background multimodal analgesia.
Drug: Melatonin
Patients receive matching oral placebo tablets administered at corresponding time points: 10:00 PM the night before surgery, 1 hour before planned spinal anesthesia, 10:00 PM on the day of surgery, and at 10:00 AM and 10:00 PM on Postoperative Day 1. All participants receive standardized spinal anesthesia and identical background multimodal analgesia.
Drug: Placebo Oral Tablet
Oral mirogabalin 10 mg tablet administered per protocol schedule (5 total doses perioperatively).
Oral melatonin 10 mg tablet administered per protocol schedule (4 active doses + 1 placebo dose at 10:00 AM POD 1).
Matching inert oral placebo tablet administered to Group P (5 total doses) and Group M (1 dose at 10:00 AM POD 1).
Postoperative Pain Intensity Scores
Assessed using the Numeric Rating Scale (NRS), where scores range from 0 to 10 (0 = "no pain", 10 = "worst possible pain"). Lower scores represent a more favorable clinical outcome (less pain intensity), whereas higher scores represent an unfavorable outcome.
Time frame: Assessed at 2, 12, 24, and 48 hours postoperatively.
Perioperative Anxiety Scores
Assessed using the anxiety subscale of the Amsterdam Preoperative Anxiety and Information Scale (APAIS). The anxiety subscale consists of 4 items rated on a 5-point Likert scale (1 = not at all, 5 = extremely), with total anxiety scores ranging from 4 to 20. Lower scores represent a more favorable clinical outcome (lower anxiety), whereas higher scores represent an unfavorable outcome.
Time frame: Preoperatively (holding area, 60-120 minutes before spinal anesthesia), and postoperatively at 2 and 12 hours.
Total Cumulative Postoperative Opioid Consumption
Total intravenous nalbuphine consumption measured in milligrams (mg) administered as rescue analgesia during the first 24 and 48 postoperative hours. Lower cumulative dose values represent a more favorable outcome (greater opioid-sparing effect).
Time frame: First 24 and 48 hours postoperatively.
Time to First Request for Rescue Analgesia
Time elapsed (in minutes) from arrival in the Post-Anesthesia Care Unit (PACU, time zero) to the first administration of rescue IV nalbuphine for NRS pain score \>= 4. Longer duration (higher values in minutes) represents a more favorable outcome (prolonged postoperative analgesia).
Time frame: Up to 48 hours postoperatively.
Postoperative Sedation Scores
Evaluated using the Modified Observer's Assessment of Alertness/Sedation (MOOA/S) scale, ranging from 0 (does not respond to deep algic stimulus) to 5 (responds readily to name spoken in normal tone). A score of 5 represents alertness (favorable recovery state), whereas lower scores indicate deeper sedation (unfavorable/excessive drug-induced sedation).
Time frame: Assessed at 2, 12, 24, and 48 hours postoperatively.
Incidence of Postoperative Nausea and Vomiting and Requirement for Rescue Antiemetics
Number of participants experiencing nausea or vomiting and requiring rescue antiemetic therapy. A lower incidence (fewer participants affected) represents a favorable outcome.
Time frame: Assessed at 2, 12, 24, and 48 hours postoperatively.
Postoperative Sleep Quality Score
Assessed using the Single-Item Sleep Quality Scale (SQS), where overall sleep quality over the 48-hour postoperative period is rated on a 0 to 10 scale (0 = terrible, 10 = excellent). Higher scores represent a more favorable outcome (better sleep quality).
Time frame: Assessed at 48 hours postoperatively.
Time to First Postoperative Mobilization
Time elapsed (in hours) from arrival in the PACU to first achieving bedside sitting and subsequent assisted ambulation. Shorter duration (lower values in hours) represents a more favorable recovery outcome.
Time frame: Up to 48 hours postoperatively.
Incidence of Treatment-Emergent Adverse Events
Number of participants experiencing adverse drug events, including dizziness, excessive somnolence, headache, pruritus, constipation, and urinary retention. A lower incidence represents a more favorable safety profile.
Time frame: Up to 48 hours postoperatively.
Incidence of Intraoperative Hypotension and Bradycardia
Number of participants experiencing spinal-anesthesia-related hypotension (mean arterial pressure drop \> 20% from baseline requiring IV fluids/ephedrine) or bradycardia (heart rate \< 50 bpm requiring IV atropine). A lower incidence represents a more favorable hemodynamic stability profile.
Time frame: Intraoperatively (from spinal injection to completion of surgery).
Patient Satisfaction With Perioperative Analgesia
Evaluated on a 5-point Likert scale (1 = very dissatisfied, 5 = very satisfied). Higher scores represent a more favorable outcome.
Time frame: Assessed at 24 hours postoperatively.
Length of Postoperative Hospital Stay
Duration of hospital stay measured in hours from completion of surgery until meeting formal discharge criteria. Shorter stay duration (lower values) represents a more favorable outcome.
Time frame: From completion of surgery (arrival in the PACU) until the date and time of meeting formal hospital discharge criteria, assessed up to 7 days postoperatively.
Plan to share: Yes — De-identified individual participant data (IPD) underlying the published results (including baseline demographics, intervention group allocation, pain scores, anxiety scores, cumulative opioid consumption, and adverse event data) will be made available to qualified researchers upon reasonable request to the
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 6 months and ending 3 years following article publication
Access criteria: Available to academic researchers who provide a methodologically sound proposal approved by the Beni-Suef University Research Ethics Committee
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.
Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 6 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirogabalin